| Bioactivity | DQP-997-74 (compound 2i) is a selective inhibitor of N-methyl-d-aspartate receptor (NMDAR), specifically targeting GluN2C/D (IC50: 0.069 μM and 0.035 μM), with Blood-brain permeability. Where DQP refers to dihydroquinoline-pyrazoline. DQP-997-74 acts synergistically with the agonist glutamate to exhibit time-dependent enhanced potency in inhibiting hypersynchronous activity driven by high-frequency excitatory synaptic transmission. DQP-997-74 reduces the number of epileptogenesis in a murine model of tuberous sclerosis complex (TSC)-induced epilepsy. DQP-997-74 can be used for research on NMDAR-related neurological diseases[1]. |
| Target | IC50: 0.069 μM (GluN2C), 0.035 μM (GluN2D), 5.2 μM (GluN2A), 16 μM (GluN2B) |
| Name | DQP-997-74 |
| CAS | 2377187-09-0 |
| Formula | C28H19Cl2F2N3O4 |
| Molar Mass | 570.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. D'Erasmo MP, et al. Development of a Dihydroquinoline-Pyrazoline GluN2C/2D-Selective Negative Allosteric Modulator of the N-Methyl-d-aspartate Receptor. ACS Chem Neurosci. 2023 Sep 6;14(17):3059-3076.. |
DQP-997-74
CAS: 2377187-09-0 F: C28H19Cl2F2N3O4 W: 570.37
DQP-997-74 (compound 2i) is a selective inhibitor of N-methyl-d-aspartate receptor (NMDAR), specifically targeting GluN2
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.